Population Screening Market Size, Share & Trends Analysis Report By Geography (Nation, State), By Product (Hardware Equipment), By Business (Hospitals), By Gender, By Type, By Age, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global population screening market size was exhibited at USD 25.27 billion in 2022 and is projected to hit around USD 43.87 billion by 2032, growing at a CAGR of 5.67% during the forecast period 2023 to 2032.

Key Pointers:

• North America dominated the market and accounted for a revenue share of 42.9% in 2022
• The nation segment dominated the market in 2022 based on geography, and it is expected to fastest growing segment over the forecast period.
• The hardware equipment (instruments, kits, chips) segment held the largest revenue share of 62.11% in 2022.
• The hospital segment accounted for the largest revenue share of 52.9% in 2022.
• The female segment held a significant revenue share in 2022. 
• The male segment dominated the market and accounted for a revenue share of 50.17% in 2022. 
• The mass segment accounted for the largest revenue share of 73.10% in 2022.
• The 15-65 years segment dominated the market and held the largest revenue share of 60.8% in 2022.

Population Screening Market Report Scope

The growth of the market is attributed to the increasing prevalence of diseases, the growing geriatric population, and increasing investment in population screening tests. Moreover, the market is expected to be driven significantly by increasing technological advancements and developments in these tests.

An increase in the prevalence of cardiovascular diseases is expected to boost segment growth. According to the WHO, 17.7 million people die annually due to cardiovascular diseases, which is 32.0% of the total deaths occurring worldwide. Cardiovascular diseases are the leading cause of mortality and morbidity in the U.S. They are among the main causes of death globally, and hypertension & its pathological adverse effects pose a significant risk for other cardiac diseases, such as heart failure & stroke. There are multiple screening programs available for material fibrillation globally that aim to reduce the mortality rate. Identifying early-stage hypertension and other CVDs is of high significance in predicting & preventing major mortality & morbidity related to these diseases.

The growing prevalence of rare genetic diseases such as Spinal Muscular Atrophy (SMA) disorders and increased spending on population screening are among the major factors for the dominance of the market. According to the National Organization for Rare Disorders (NORD), SMA affects almost one in 10,000 people globally. In addition, according to SMA Canada, approximately 700 people were living with this condition in Canada as of July 2022. For instance, the CDC released the Recommended Uniform Screening Panel (RUSP) to states under its statewide universal newborn programs for the early identification of children with SMA. Thus, such initiatives are undertaken by governments to screen the population, thereby supporting the growth of the population screening market.

Players in the market adopt the strategy of product launches to strengthen their product portfolio and offer diverse, technologically advanced, & innovative population screening products to patients. Several market players engage in mergers & acquisitions to strengthen their market position. This strategy enables companies to boost their capabilities, expand product portfolios, and improve competencies. For instance, in August 2022, Thermo Fisher Scientific, Inc., launched an HIV-1 genotyping kit to identify the genetic mutations that resist Antiretroviral Therapeutics (ART). This kit was intended only for research purposes.

Population Screening Market Segmentation